Additional file 1: of Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells

Abstract

Figure S1. Dose–response curves for sorafenib without or with the indicated selumetinib concentrations. Viability was measured by SRB assay after 10 days drug exposure and normalized to untreated controls (mean values +/− SEM). The respective combination indices (CI) were calculated by CompuSyn Software and are shown in Fig. 1c. (EPS 4764 kb